Pharmaceuticals

Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange

SHANGHAI, July 10, 2020 /PRNewswire/ -- Ocumension Therapeutics ("Ocumension"), aChina-based ophthalmic pharmaceutical platform company, has today launched its Initial Public Offering (IPO) of the company's stock on The Stock Exchange of Hong Kong (HKEX). Ocumension plans to offer 105,930,000 shar...

2020-07-10 21:55 17798

CS02 Changes the Landscape of Diabetes Treatment: CenterLab Announces Positive Topline Results of Phase 2 Trial

TAIPEI, July 10, 2020 /PRNewswire/ -- Center Laboratories Inc. (CenterLab: 4123.TWO), a pharmaceutical company dedicated in specialty drug product development, announced today that the anti-diabetic drug – CS02 meets its primary endpoint. The topline results of a phase 2 clinical trial of CS02...

2020-07-10 20:43 1802

Merck Opens its Largest M Lab™ Collaboration Center in Shanghai

-- Focus on improving and optimizing drug discovery, development and manufacturing -- Integrated lab with customizable solutions, validation services, training and hands-on applications -- Shanghai center is newest and largest addition to Merck's global network of nine M Lab™ Collaboration Cente...

2020-07-10 13:00 1310

Carromex Unveils Pharma Leads, a Groundbreaking Cloud-based Platform for Rapid Drug Analysis and Discovery

SYDNEY and MELBOURNE, Australia, July 9, 2020 /PRNewswire/ -- Carromex, a mathematical research-based innovation company based inAustralia, unveiled a new cloud-based pharmaceutical software platform called Pharma Leads  https://carromex.com/products/pharma-leads/

2020-07-10 11:31 471

Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus

SINGAPORE, July 9, 2020 /PRNewswire/ -- Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. Testing has demo...

2020-07-09 21:27 1545

Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)

SHANGHAI, July 8, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today it has received Clinical Trial Ap...

2020-07-08 22:00 606

Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis

STOCKHOLM, July 8, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to c...

2020-07-08 14:57 916

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China

SHANGHAI, July 8, 2020 /PRNewswire/ -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced an...

2020-07-08 11:37 809

ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States

DAEJEON, South Korea, July 7, 2020 /PRNewswire/ -- ILIAS Biologics Inc. (the "Company" or "ILIAS"), a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO). A patent...

2020-07-08 01:00 521

Ascentage Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate APG-115 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., July 6, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the com...

2020-07-06 13:00 524

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.

SUZHOU, China, July 2, 2020 /PRNewswire/ -- CF PharmTech, Inc. ("CF PharmTech") announced today that it has raised US $50M in Series F financing following its US$90M Series E financing in January of 2020, in total, successfully completing an equity investment deal of nearly US$140M within six mon...

2020-07-02 09:00 1936

­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

SHANGHAI and PHILADELPHIA, July 1, 2020 /PRNewswire/ --Antengene Corporation today announced its appointment of Zhinuan Yu, Ph.D., as Corporate Vice President (CVP) of Biometrics and Regulatory Enabling Functions. Zhinuan will be responsible for providing statistical leadership and strategic r...

2020-07-02 08:16 591

Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US

SUZHOU, China, July 1, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successfull...

2020-07-01 23:00 540

Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19

TAIPEI and SAN DIEGO, July 1, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that its drug Silmitasertib was again identified as o...

2020-07-01 21:00 1563

A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac")  is published in the June edition of MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in RhoVac's achievements as well as plans for t...

2020-07-01 20:41 972

Yiling Pharmaceutical Lianhua Qingwen Capsule Extends Overseas Footprint in Southeast Asia

SHIJIAZHUANG, China, July 1, 2020 /PRNewswire/ -- Following Thailand, Singapore andIndonesia, Yiling Pharmaceutical (002603.SZ), a leader in the development of traditional Chinese medicines (TCM), obtained a Certificate of Registration issued by the Drug Department ofLaos' Ministry of Health whic...

2020-07-01 20:33 5501

RhoVac Marketed in International Press

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in Rh...

2020-07-01 15:49 749

Clarivate Introduces Next Generation Insights Platform with Cortellis Generics Intelligence

LONDON, July 1, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch ofCortellis Generics Intelligence™ to enable generics companies and Active Pharmaceutical Ingredient (API) ...

2020-07-01 15:00 5802

Lipidor AB (publ) Formalizes Relationship With Subsidiary Emollivet AB Through License Agreement and Proposes Financing of Subsidiary

STOCKHOLM, Sweden, July 1, 2020 /PRNewswire/ -- Lipidor AB ("Lipidor" or the " Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology. OnJune 30, Emollivet's Ext...

2020-07-01 08:06 811

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

DARMSTADT, Germany and NEW YORK, July 1, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with...

2020-07-01 07:30 6375
1234567 ... 126